Antidepressants versus placebo for generalised anxiety disorder (GAD)

广泛性焦虑症 耐受性 安慰剂 抗抑郁药 焦虑 不利影响 精神科 精神药理学 随机对照试验 医学 内科学 替代医学 病理
作者
Katarina Kopcalic,Justin A. Arcaro,Antonio Pinto,Shehzad Ali,Corrado Barbui,Chiara Curatoli,Janet E Martin,Giuseppe Guaiana
出处
期刊:The Cochrane library [Elsevier BV]
卷期号:2025 (2): CD012942-CD012942 被引量:26
标识
DOI:10.1002/14651858.cd012942.pub2
摘要

BACKGROUND: Generalised anxiety disorder (GAD) is a mental health condition characterised by excessive anxiety and worry about everyday events. GAD is a common disorder and generally affects women twice as often as men. Treatments include various psychological and pharmacological therapies. Among the pharmacological therapies, antidepressants, in particular, selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), are commonly used for the treatment of GAD and many studies have shown their benefit over placebo. Only one systematic review and meta-analysis comparing all antidepressants to placebo has been done in the past. Since then, new data on existing antidepressants have emerged and new antidepressants have been introduced. An updated and more comprehensive review is needed to provide a stronger understanding of the efficacy, acceptability, tolerability, and impact on the quality of life of the various types of antidepressants compared to placebo. OBJECTIVES: To assess the effects of antidepressants in GAD in adults, specifically: to determine the efficacy of antidepressants in alleviating symptoms of GAD compared to placebo and to review the acceptability of antidepressants in GAD in terms of adverse effects, including the general prevalence of adverse effects compared to placebo. SEARCH METHODS: We searched the Cochrane Common Mental Health Disorders (CCMD) register, CENTRAL, MEDLINE, Embase, PsycINFO, and two trials registers in October 2022. SELECTION CRITERIA: We included randomised controlled trials (RCT) or cluster-RCTs that randomly assigned participants to receive either an antidepressant or placebo for the treatment of GAD. There were no restrictions on dose, frequency, intensity, or duration of treatment. The studies included adults of either sex with a primary diagnosis of GAD and without any serious medical comorbidities. Psychiatric comorbidities were allowed as long as GAD was the primary diagnosis. We excluded studies investigating psychotherapies and those that included participants who had regular use of benzodiazepines. There were no restrictions on setting, country, or language. DATA COLLECTION AND ANALYSIS: Two review authors independently checked eligibility and extracted data following standard Cochrane methodological procedures. We assessed risk of bias using the Cochrane RoB 1 tool. A third review author resolved disagreements between the two primary review authors. We extracted study characteristics, participant characteristics, intervention details, settings, and outcome measures regarding efficacy, acceptability, tolerability, and quality of life. We used GRADE to assess the certainty of the evidence. MAIN RESULTS: We included 37 unique RCTs with 12,226 participants in the review. The studies included adults with moderate-severe GAD and without any serious medical comorbidities. Few studies included participants with secondary psychiatric comorbidities. The double-blind treatment duration ranged from four weeks to 28 weeks. Antidepressants have a benefit over placebo on rate of treatment response measured as a reduction of at least 50% on the Hamilton Anxiety Rating Scale (HAM-A) (risk ratio (RR) 1.41, 95% confidence interval (CI) 1.29 to 1.55; 20 studies, 7267 participants; high-certainty evidence). The magnitude of effect corresponds to a number needed to treat for an additional beneficial outcome (NNTB) of 7 (95% CI 5 to 9). Antidepressants have no difference in acceptability compared to placebo, measured as the number of participants who dropped out during the trial as a proportion of the total number of randomised participants (RR 1.03, 95% CI 0.93 to 1.14; 33 studies, 11,294 participants; high-certainty evidence). Fewer participants dropped out due to a lack of efficacy in the antidepressant group compared to the placebo group (RR 0.41, 95% CI 0.33 to 0.50; 29 studies, 11,007 participants; high-certainty evidence) with an NNTB of 27 (95% CI 24 to 32), and more participants dropped out due to adverse effects in the antidepressant group compared to placebo (RR 2.18, 95% CI 1.81 to 2.61; 32 studies, 11,793 participants; high-certainty evidence) with a number needed to treat for an additional harmful outcome (NNTH) of 17 (95% CI 13 to 112). We observed similar findings when classes of antidepressants were compared with placebo. The certainty of the evidence for the analyses comparing different classes of antidepressants to placebo was high. AUTHORS' CONCLUSIONS: This review added to the growing literature on antidepressants in the treatment of GAD. We have high confidence that antidepressants are more effective than placebo at improving treatment response and that antidepressants have similar acceptability to placebo. Fewer participants dropped out due to a lack of efficacy in the antidepressant group compared to the placebo group and more participants dropped out due to adverse effects in the antidepressant group compared to placebo. We are highly confident in this evidence. This review identified some important gaps in the literature on antidepressants for GAD and can be used as a tool to guide future research. Future studies may be more transparent with their methodology and outcome reporting. Future reviews may also include people with comorbidities, and explore other sources of heterogeneity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桃之夭夭完成签到,获得积分20
刚刚
1秒前
1秒前
可颂猫猫完成签到,获得积分10
2秒前
锦鲤完成签到,获得积分10
3秒前
传奇3的应助被LioraY采纳,获得10
3秒前
oreo发布了新的文献求助10
3秒前
3秒前
脑洞疼的应助被阿咸采纳,获得20
4秒前
4秒前
粗犷的青槐完成签到,获得积分10
4秒前
4秒前
聪明的元枫完成签到,获得积分10
5秒前
科研通AI2S的应助被chen采纳,获得10
5秒前
Eternal发布了新的文献求助10
5秒前
6秒前
river发布了新的文献求助10
6秒前
6秒前
姗姗完成签到,获得积分10
6秒前
msk发布了新的文献求助10
6秒前
天空发布了新的文献求助10
7秒前
爆米花的应助被xiao采纳,获得10
7秒前
8秒前
槿轩完成签到,获得积分10
8秒前
8秒前
无极微光的应助被了了采纳,获得20
9秒前
孟格格完成签到,获得积分10
9秒前
光合谷发布了新的文献求助10
9秒前
Harvest发布了新的文献求助10
9秒前
orixero的应助被争取SCI采纳,获得10
10秒前
桃之夭夭发布了新的文献求助10
10秒前
karma完成签到 ,获得积分10
10秒前
斯文败类的应助被51515采纳,获得10
10秒前
顾矜的应助被muyou采纳,获得10
10秒前
希望天下0贩的0的应助被嘟嘟采纳,获得10
10秒前
123发布了新的文献求助10
11秒前
11秒前
11秒前
11秒前
负责御姐完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178375
求助须知:如何正确求助?哪些是违规求助? 9569182
关于积分的说明 21802781
捐赠科研通 7773247
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556793
邀请新用户注册赠送积分活动 2478346